Related Experiment Videos
[Phase II study of CIS-diamminedichloroplatinum (II) by collaborative study]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|April 1, 1982
Summary
Cisplatin demonstrated significant efficacy in treating ovarian malignancies, achieving a 58% overall response rate. However, notable toxicities including gastrointestinal issues, myelosuppression, and renal dysfunction were observed.
Area of Science:
- Oncology
- Pharmacology
Context:
- Platinum compounds, including cisplatin, have shown promise as anticancer agents.
- Clinical trials for cisplatin in treating testicular and ovarian cancers are ongoing globally.
- Ovarian malignancies represent a significant area of oncological research and treatment.
Purpose:
- To evaluate the efficacy and toxicity of cisplatin (NK-801) in a joint controlled trial for ovarian malignancies.
- To assess patient response rates based on established criteria.
Summary:
- A joint controlled trial involved 57 evaluable patients with ovarian malignancies treated with cisplatin.
- Complete response was observed in 11% of patients, partial response in 47%, leading to an overall response rate of 58%.
- Adverse effects included gastrointestinal toxicities, myelosuppression, and renal dysfunction.
Impact:
- Cisplatin shows considerable therapeutic potential for ovarian cancer patients.
- Understanding the toxicity profile is crucial for managing patients undergoing cisplatin treatment.
- This trial contributes valuable data to the ongoing research of platinum-based chemotherapy in gynecological cancers.